Skip to main content

Table 3 Summary of adverse events

From: Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression

 

Quetiapine XR (n = 179)

Number of Patients (%)

Number of AEs

AEs

171 (95.5%)

845

Drug-related AEs

159 (88.8%)

559

Deaths

0

SAEs

5 (2.8%)

6

Drug-related SAEs

2 (1.1%)

2

AEs leading to discontinuation

51 (28.5%)

64

Drug-related AEs leading to discontinuation

39 (21.8%)

49

  1. AEs adverse events, SAEs serious adverse events